Recludix Pharma

Recludix Pharma is a private, pre-clinical stage biotech leveraging a proprietary, integrated drug discovery platform to target previously undruggable protein domains, specifically SH2 domains. The company's platform combines custom DNA-encoded libraries, massively parallel structure-activity relationship determination, and a selectivity screening tool to develop novel therapeutics for inflammatory and oncological diseases. Led by industry veterans from companies like Seagen and Blueprint Medicines, Recludix is advancing a pipeline with initial programs targeting STAT6 and BTK, aiming to address significant unmet medical needs in immunology and oncology.

Integrated drug discovery platform combining custom DNA-encoded libraries, massively parallel structure-activity relationship determination, and a proprietary selectivity screening tool to develop inhibitors of challenging targets like SH2 domains.

Recludix competes in crowded therapeutic areas but aims for differentiation through its novel SH2 domain platform. It faces competition from large pharma and biotech companies with approved and clinical-stage biologics, JAK inhibitors, and BTK inhibitors, but its mechanism, if proven, could be first-in-class.